Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I

Immunologic Research

Volumn 61, Issue 1-2, 2015, Pages 35-44

  Artenjak, A ^a   Locatelli, I ^b   Brelih, H ^c   Simonic D M ^c   Ulcova Gallova, Z ^d   Swadzba, J ^e   Musial, J ^e   Iwaniec, T ^e   Stojanovich, L ^f   Conti, F ^g   Valesini, G ^g   Avcin T ^h   Cohen Tervaert, J W ⁱ   Shoenfeld, Y ^j   Blank, M ^j,k   Ambrozic A ^c   Sodin Semrl, S ^c,l   Bozic B ^b,c   Cucnik S ^c  

^a Lek Pharmaceuticals Dd   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d CHARLES UNIVERSITY   (Czech Republic)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

ⁱ MAASTRICHT UNIVERSITY   (Netherlands)

^j SHEBA MEDICAL CENTER   (Israel)

^k TEL AVIV UNIVERSITY   (Israel)

^l UNIVERSITY OF PRIMORSKA   (Slovenia)

more..

Author keywords

Anti 2GPI antibodies; Anti 2GPI related peptides antibodies; Antiphospholipid syndrome; Avidity; 2GPI peptides

Indexed keywords

AMINO ACID; AMINO ACID DERIVATIVE; ASPARAGINYLGLYCYLPROLYLALANYLASPARAGINYLSERYLLYSINE; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; EPITOPE; HEXAPEPTIDE; IMMUNOGLOBULIN G ANTIBODY; LEUCYLLYSYLTHREONYLPROLYLARGINYLVALINE; LYSYLASPARTYLLYSYLALANYLTHREONYLPHENYLALANINE; LYSYLMETHIONYLASPARTYLGLYCYLASPARAGINYLHISTIDYLPROLINE; PEPTIDE ANTIBODY; THREONYLLEUCYLARGINYLVALYLTYROSYLLYSINE; TYROSYLASPARAGINYLPROLYLLEUCYLTRYPTOPHYLPHENYLALANYLVALINE; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN G; PEPTIDE; PROTEIN BINDING;

ADOLESCENT; ADULT; AGED; AMINO ACID ANALYSIS; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PHAGE DISPLAY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DOMAIN; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; ANTIBODY AFFINITY; BLOOD; CHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RISK; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY AFFINITY; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDES; PROTEIN BINDING; YOUNG ADULT;

EID: 84925490713     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8578-0     Document Type: Article

References (41)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. doi:10.1111/j.1538-7836.2006.01753.x.
2. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11. doi:10.1002/1529-0131(199907)42:7<1309:AID-ANR1>3.0.CO;2-F.
3. Cervera R, Asherson RA. Antiphospholipid syndrome. In: Shoenfeld Y, Cervera R, Gershwin ME, editors. Diagnostic criteria in autoimmune diseases. Totowa: Humana Press; 2008. p. 9–14.
4. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27. doi:10.1002/art.10187.
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
7. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330–9. doi:10.1038/nrrheum.2011.52.
8. de Laat B, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol. 2008;4(4):192–9. doi:10.1038/ncprheum0740.
9. Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol. 2010;6(5):296–300. doi:10.1038/nrrheum.2010.47.
10. Artenjak A, Lakota K, Frank M, Cucnik S, Rozman B, Bozic B, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev. 2012;11(12):873–82. doi:10.1016/j.autrev.2012.03.002.
11. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337–47. doi:10.1161/CIRCULATIONAHA.104.507996.
12. Lin F, Murphy R, White B, Kelly J, Feighery C, Doyle R, et al. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus. 2006;15(2):87–93.
13. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation. 2009;6:3. doi:10.1186/1742-2094-6-3.
14. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA. 1984;81(12):3640–4.
15. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA. 1993;90(6):2141–5.
16. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18(22):6228–39. doi:10.1093/emboj/18.22.6228.
17. Sodin-Semrl S, Frank M, Ambrožič A, Pavlič J, Šuštar V, Čučnik S, et al. Interactions of phospholipid binding proteins with negatively charged membranes: β2-glycoprotein I as a model mechanism. In: Leitmannova Liu A, editor. Advances in planar lipid bilayers and liposomes, 1st ed. Amsterdam: Elsevier; 2008. p. 243–73.
18. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336–43. doi:10.1182/blood-2009-12-260976.
19. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107(5):1916–24. doi:10.1182/blood-2005-05-1943.
20. Wang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol. 1995;155(3):1629–36.
21. Kasahara H, Matsuura E, Kaihara K, Yamamoto D, Kobayashi K, Inagaki J, et al. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol. 2005;17(12):1533–42. doi:10.1093/intimm/dxh330.
22. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012;12(2):313–7. doi:10.1016/j.autrev.2012.05.006.
23. Ambrozic A, Avicin T, Ichikawa K, Kveder T, Matsuura E, Hojnik M, et al. Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol. 2002;14(7):823–30.
24. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis. 2004;63(11):1478–82. doi:10.1136/ard.2003.017939.
25. de Laat B, Derksen RH, de Groot PG. High-avidity anti-beta2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta2 glycoprotein I antibodies. J Thromb Haemost. 2006;4(7):1619–21. doi:10.1111/j.1538-7836.2006.02002.x.
26. Zager U, Irman S, Lunder M, Skarabot M, Musevic I, Hodnik V, et al. Immunochemical properties and pathological relevance of anti-beta2-glycoprotein I antibodies of different avidity. Int Immunol. 2011;23(8):511–8. doi:10.1093/intimm/dxr043.
27. Zager U, Lunder M, Čučnik S, Kveder T, Rozman B, Božič B. Immunodominant epitopes of beta2-glycoprotein I for high avidity antibodies. In: 8th International congress on autoimmunity. Granada, Spain: Geneva: Kenes International; 2012.
28. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA. 1999;96(9):5164–8.
29. Cucnik S, Kveder T, Artenjak A, Ulcova Gallova Z, Swadzba J, Musial J, et al. Avidity of anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus. 2012;21(7):764–5. doi:10.1177/0961203312440057.
30. Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun. 2006;27(4):266–71. doi:10.1016/j.jaut.2006.09.007.
31. Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol. 2003;23(5):377–83.
32. Cucnik S, Bozic B, Kveder T, Tomsic M, Rozman B. Avidity of anti-beta2-glycoprotein I and thrombosis or pregnancy loss in patients with antiphospholipid syndrome. Ann N Y Acad Sci. 2005;1051:141–7. doi:10.1196/annals.1361.055.
33. Cucnik S, Kveder T, Ulcova-Gallova Z, Swadzba J, Musial J, Valesini G, et al. The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus. 2011;20(11):1166–71. doi:10.1177/0961203311406308.
34. Artenjak A, Kozelj M, Lakota K, Cucnik S, Bozic B, Sodin-Semrl S. High avidity anti-b2-glycoprotein I antibodies activate human coronary artery endothelial cells and trigger peripheral blood mononuclear cell migration. Eur J Inflamm. 2013;11(2):385–96.
35. Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med. 2011;49(3):447–61. doi:10.1515/CCLM.2011.064.
36. Cucnik S, Ambrozic A, Bozic B, Skitek M, Kveder T. Anti-beta2-glycoprotein I ELISA: methodology, determination of cut-off values in 434 healthy Caucasians and evaluation of monoclonal antibodies as possible international standards. Clin Chem Lab Med. 2000;38(8):777–83. doi:10.1515/CCLM.2000.111.
37. Avcin T, Ambrozic A, Bozic B, Accetto M, Kveder T, Rozman B. Estimation of anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20(1):101–8.
38. Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E, et al. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res. 2011;128(6):583–6. doi:10.1016/j.thromres.2011.04.021.
39. Muller C, Thaler M, Schlichtiger A, Schreiegg A, Balling G, Steigerwald U, et al. beta2-glycoprotein I-derived peptides as antigenic structures for the detection of antiphospholipid antibodies. J Thromb Haemost. 2010;8(9):2073–5. doi:10.1111/j.1538-7836.2010.03987.x.
40. Metzger J, von Landenberg P, Kehrel M, Buhl A, Lackner KJ, Luppa PB. Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem. 2007;53(6):1137–43. doi:10.1373/clinchem.2006.079632.
41. Pierangeli SS, Blank M, Liu X, Espinola R, Fridkin M, Ostertag MV, et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun. 2004;22(3):217–25. doi:10.1016/j.jaut.2004.01.002.